Herantis Pharma's clinical study with Lymfactin advances to high dose level
(Thomson Reuters ONE) -
Herantis Pharma's clinical study with Lymfactin advances to high dose level
Herantis Pharma Plc
Company release 6 March 2017 at 10:00 am
Herantis Pharma Plc's ("Herantis") clinical study with the company's innovative
gene therapy investigational product Lymfactin® for the treatment of secondary
lymphedema has advanced to highest planned dose level owing to good reported
safety. A Data Monitoring Committee of independent experts recommended
proceeding to high dose treatments after assessing safety data on the previously
treated patients. Following the recommendation, the first high dose treatment
has already been administered.
"We are naturally very happy for the safety of Lymfactin® in the first
treatments", comments Pekka Simula, Herantis' CEO. "This is the first clinical
study in the world to apply gene therapy for repairing damages of the lymphatic
system. Safety of the patients is our #1 priority so we want to move ahead
carefully. We are thrilled to announce this milestone by coincidence on March
6: World Lymphedema Day!"
"Collaboration with the participating university hospitals in this study has
been excellent", adds Katarina Jääskeläinen, Herantis' Project Manager for the
clinical study. "Secondary lymphedema is a disfiguring, disabling disease that
severely impacts the quality of life of patients. We hope our Lymfactin® will
significantly improve the quality of life of patients in the future."
The Phase 1 clinical study continues recruiting patients with breast cancer
associated lymphedema at three university hospitals in Finland: In Helsinki,
Tampere, and Turku. The study intends to recruit at most 18 patients by the end
of 2017.
Further information:
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Herantis Pharma Plc, Katarina Jääskeläinen, Project Manager,
telephone +358 50 3055 582
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
World Lymphedema Day
March 6 was officially recognized World Lymphedema Day since 2015 by e.g. the
U.S. Senate. It is celebrated around the world largely thanks to the patient
advocacy group Lymphatic Education & Research Network (LE&RN) to increase
lymphedema awareness. Learn more by visiting the website lymphaticnetwork.org.
About breast-cancer associated lymphedema
Approximately 20% of breast cancer patients who undergo axillary lymph node
dissection develop secondary lymphedema, a chronic, progressive, disabling and
disfiguring disease that severely affects quality of life. Symptoms include a
chronic swelling of an upper limb, thickening and hardening of skin, loss of
mobility and flexibility, pain, and susceptibility to secondary infections.
Secondary lymphedema is currently treated with compression garments, special
massage, and exercises. While these therapies may relief the symptoms in some
patients they do not cure lymphedema, which is caused by damage to the lymphatic
system. There are currently no approved medicines for the treatment of this
condition.
About Lymfactin®
Lymfactin® is a gene therapy expressing the growth factor VEGF-C specific to the
development of lymphatic vessels. Based on preclinical studies Lymfactin®
triggers the growth of new functional lymphatic vasculature in the damaged area
and thus repairs the underlying cause of secondary lymphedema. Lymfactin®,
patented by Herantis, is based on the internationally renowned scientific
research of academy professor Kari Alitalo and his research group, a national
centre of excellence at the University of Helsinki. Herantis also holds patents
for a combination therapy, which may expand the use of Lymfactin® in other
lymphedemas. See our introductory video on Lymfactin®:
http://herantis.com/media/videos/
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on
regenerative medicine and unmet clinical needs. Our first-in-class assets are
based on globally leading scientific research in their fields: CDNF for disease
modification in neurodegenerative diseases, primarily Parkinson's and ALS; and
Lymfactin® for breast cancer associated lymphedema, with potential also in
primary lymphedema. The shares of Herantis are listed on the First North Finland
marketplace run by Nasdaq Helsinki Ltd.
Distribution:
Nasdaq Helsinki
Main media
www.herantis.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.03.2017 - 09:00 Uhr
Sprache: Deutsch
News-ID 528225
Anzahl Zeichen: 5514
contact information:
Town:
Helsinki
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Herantis Pharma's clinical study with Lymfactin advances to high dose level"
steht unter der journalistisch-redaktionellen Verantwortung von
Herantis Pharma Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
